The trial was evaluating HyBryte in a rare form of cancer with limited treatment options. ・The company also plans to assess ...

Soligenix reported that a phase three trial of its HyBryte treatment for cutaneous T-cell lymphoma missed expectations and was recommended to halt for futility. "Despite the fact that HyBryte ...

Soligenix (NASDAQ: SNGX) announced the European Commission has granted orphan drug designation to dusquetide (SGX945) for the treatment of Behçet Disease, following a positive recommendation from the ...

PRINCETON, N.J., March 26, 2026 /PRNewswire/ --Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

A Bengaluru teenager has successfully undergone a rare surgery to repair a life-threatening aortic aneurysm caused by ...

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...

The EULAR recommendations for the management of Behçet's syndrome were first published in 2008, and updated in 2018. Since that time, new evidence has become available, including trials of biologic ...

Strengthens Pipeline As European Commission Grants SGX945 Orphan Status. Designations from established global organizations such as the European Commission carry meaningful implications for ...

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing ...

Soligenix announced that the European Commission granted orphan drug designation to SGX945 for the treatment of Behçet’s ...